Skip to content
← Full study record

NCT01303965 · MORE INFO

Limitations, agreements, and source contact

Allo Transplant Followed by Lenalidomide and Sirolimus Maintenance in High-Risk Multiple Myeloma (MM) · Source last updated 2019-01-08

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
pi Sponsor Employee
true
point Of Contact
email
ssfarag@iu.edu
organization
IndianaU
phone
(317) 278-0460
title
Dr. Sherif Farag
Complete source fields
certain Agreement
pi Sponsor Employee
true
point Of Contact
email
ssfarag@iu.edu
organization
IndianaU
phone
(317) 278-0460
title
Dr. Sherif Farag

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice